Optovue receives $30M in financing to help market OCT angiography technology

Nov. 23, 2015

Optovue has received $30 million in funding to help commercialize its AngioVue OCT angiography system.

Optical coherence tomography (OCT) technology developer Optovue (Fremont, CA) has executed an agreement to receive $30 million in private equity funding from Deltronics (Netherlands) B.V., a subsidiary of Delta Electronics. The funding will enable Optovue to expand its current imaging platforms, and to further the commercialization and development of applications for its AngioVue OCT angiography system. This long-term investment also allows Delta to extend its strategic reach into the healthcare industry.

Related: OCT angiography: A new approach with 'gold standard' capabilities and more

OCT angiography gives physicians the ability to visualize blood vessels in the individual layers of the retina without injections of dye, says Jay Wei, founder and CEO for Optovue. “This visualization information provides physicians with a compelling new way to manage patients affected by wet age-related macular degeneration, a leading cause of blindness. We expect similar contributions to the management of diabetic retinopathy, the leading cause of blindness in diabetic patients,” he adds.

The AngioVue system, introduced to markets outside of the U.S. in late 2014, is now in daily clinical use at over 400 sites. With applications including retina, glaucoma, and anterior segment, AngioVue technology has been the focus of over 50 peer-reviewed scientific publications.

For more information, please visit www.optovue.com.

Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)